2025 NOSCM | What is New in EGFR and ALK NSCLC?

2025 NOSCM | What is New in EGFR and ALK NSCLC?

0% Complete

Course Overview

Dr. Julia Rotow updated on EGFR and ALK mutations, stressing the use of osimertinib and lorlatinib.

Course Content

Credits

  • AMA PRA Category 1 Creditâ„¢Non-CME

Course Details

Duration
0.00 hour
Released
Jul 25, 2025
Last Review
Jul 25, 2025
Expires
Jul 25, 2026

Target Audience

Physicians
Nurses
Pharmacists
Physician Associates

Faculty & Disclosure

Faculty

Julia Rotow, MD

Accreditation

NA